Generic Name and Formulations:
Methyl aminolevulinate 16.8%; crm.
Galderma Laboratories, Inc.
Indications for METVIXIA:
For treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratoses of the face and scalp in immunocompetent patients, in combination with Aktilite CL128 lamp red light illumination.
See literature. Surface of lesion should be prepared before applying. Use nitrile gloves. Apply a layer of cream about 1mm thick to lesion and surrounding 5mm of normal skin. Do not apply more than 1g (half tube) per treatment session. Cover area with occlusive, non-absorbent dressing for 3 hours. Multiple lesions may be treated during the same session. Remove occlusive dressing and clean area with saline and gauze. Position Aktilite CL128 lamp. Required illumination time: 7–10 minutes. Keep area covered and away from light for at least 48 hours after. Two treatment sessions one week apart should be administered. Assess lesion response 3 months after the last treatment session.
<18yrs: not recommended.
Cutaneous photosensitivity. Porphyrin, peanut, or almond oil allergy.
Do not apply to eyes, mucous membranes. Avoid exposure to sunlight or bright indoor light during the period prior to Aktilite red light treatment. If red light treatment cannot be administered, remove cream and protect skin from sunlight or intense light for two days. Coagulation defects. Pregnancy (Cat.C). Nursing mothers.
Additive photosensitivity possible with concomitant photosensitizing agents.
Erythema, pain, burning and discomfort, pruritus, scabbing, crusting and erosions, edema and exfoliation of skin.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|